News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
292,391 Results
Type
Article (14962)
Company Profile (33)
Press Release (277396)
Multimedia
Podcasts (20)
Webinars (4)
Section
Business (80565)
Career Advice (1333)
Deals (15979)
Drug Delivery (34)
Drug Development (48452)
Employer Resources (54)
FDA (7747)
Job Trends (6487)
News (151290)
Policy (12619)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Standard (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (1)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
Academia (1008)
Accelerated approval (4)
Adcomms (11)
Allergies (58)
Alliances (15226)
ALS (51)
Alzheimer's disease (706)
Antibody-drug conjugate (ADC) (93)
Approvals (7805)
Artificial intelligence (143)
Autoimmune disease (19)
Automation (9)
Bankruptcy (117)
Best Places to Work (5669)
BIOSECURE Act (4)
Biosimilars (62)
Biotechnology (26)
Bladder cancer (58)
Brain cancer (22)
Breast cancer (231)
Cancer (1613)
Cardiovascular disease (116)
Career advice (1036)
Career pathing (11)
CAR-T (73)
Cell therapy (227)
Cervical cancer (16)
Clinical research (41990)
Collaboration (496)
Compensation (344)
Complete response letters (10)
COVID-19 (1221)
CRISPR (18)
C-suite (103)
Cystic fibrosis (44)
Data (1639)
Denatured (1)
Depression (25)
Diabetes (176)
Diagnostics (2704)
Digital health (12)
Diversity, equity & inclusion (11)
Drug discovery (67)
Drug pricing (25)
Drug shortages (9)
Duchenne muscular dystrophy (65)
Earnings (50431)
Editorial (14)
Employer branding (8)
Employer resources (47)
Events (47144)
Executive appointments (391)
FDA (8581)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (3)
Frontotemporal dementia (4)
Funding (446)
Gene editing (50)
Generative AI (9)
Gene therapy (175)
GLP-1 (432)
Government (1649)
Grass and pollen (5)
Guidances (41)
Healthcare (8161)
Huntington's disease (15)
IgA nephropathy (21)
Immunology and inflammation (71)
Indications (23)
Infectious disease (1310)
Inflammatory bowel disease (71)
Inflation Reduction Act (5)
Influenza (37)
Intellectual property (53)
Interviews (249)
IPO (9655)
IRA (11)
Job creations (1184)
Job search strategy (910)
Kidney cancer (9)
Labor market (18)
Layoffs (197)
Leadership (10)
Legal (2036)
Liver cancer (50)
Lung cancer (241)
Lymphoma (126)
Machine learning (5)
Management (17)
Manufacturing (139)
MASH (55)
Medical device (5871)
Medtech (5871)
Mergers & acquisitions (6728)
Metabolic disorders (431)
Multiple sclerosis (59)
NASH (17)
Neurodegenerative disease (60)
Neuropsychiatric disorders (15)
Neuroscience (1045)
NextGen: Class of 2025 (2417)
Non-profit (2088)
Northern California (1787)
Now hiring (4)
Obesity (208)
Opinion (94)
Ovarian cancer (52)
Pain (55)
Pancreatic cancer (66)
Parkinson's disease (95)
Partnered (4)
Patents (114)
Patient recruitment (69)
Peanut (33)
People (13406)
Pharmaceutical (13)
Pharmacy benefit managers (3)
Phase I (10436)
Phase II (17246)
Phase III (17888)
Pipeline (976)
Policy (40)
Postmarket research (1374)
Preclinical (3506)
Press Release (18)
Prostate cancer (79)
Psychedelics (13)
Radiopharmaceuticals (126)
Rare diseases (229)
Real estate (1535)
Recruiting (21)
Regulatory (10086)
Reports (26)
Research institute (922)
Resumes & cover letters (256)
Rett syndrome (4)
RNA editing (1)
RSV (32)
Schizophrenia (53)
Series A (71)
Series B (51)
Service/supplier (5)
Sickle cell disease (35)
Southern California (1498)
Special edition (15)
Spinal muscular atrophy (106)
Sponsored (14)
Startups (1080)
Stomach cancer (6)
Supply chain (44)
Tariffs (10)
The Weekly (19)
United States (13994)
Vaccines (371)
Venture capitalists (22)
Weight loss (118)
Women's health (15)
Worklife (10)
Date
Today (76)
Last 7 days (425)
Last 30 days (1724)
Last 365 days (21099)
2025 (6870)
2024 (20538)
2023 (21229)
2022 (25568)
2021 (26883)
2020 (25280)
2019 (20186)
2018 (15167)
2017 (15632)
2016 (13557)
2015 (16116)
2014 (11829)
2013 (8845)
2012 (9257)
2011 (9743)
2010 (8375)
Location
Africa (375)
Alabama (19)
Alaska (3)
Arizona (44)
Arkansas (8)
Asia (20647)
Australia (3863)
California (3979)
Canada (1117)
China (343)
Colorado (173)
Connecticut (192)
Delaware (114)
Europe (42525)
Florida (502)
Georgia (123)
Idaho (18)
Illinois (303)
India (16)
Indiana (175)
Iowa (5)
Japan (138)
Kansas (53)
Kentucky (5)
Louisiana (6)
Maine (36)
Maryland (431)
Massachusetts (2818)
Michigan (81)
Minnesota (220)
Mississippi (2)
Missouri (48)
Montana (12)
Nebraska (6)
Nevada (37)
New Hampshire (34)
New Jersey (1159)
New Mexico (8)
New York (1071)
North Carolina (547)
North Dakota (3)
Northern California (1787)
Ohio (108)
Oklahoma (3)
Oregon (15)
Pennsylvania (789)
Puerto Rico (6)
Rhode Island (13)
South America (544)
South Carolina (9)
Southern California (1498)
Tennessee (57)
Texas (568)
Utah (94)
Virginia (92)
Washington D.C. (31)
Washington State (369)
West Virginia (1)
Wisconsin (46)
292,391 Results for "3".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
SpringWorks Surges on Potential $3.5B Merck KGaA Buyout
The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling approximately $3.5 billion for the acquisition.
April 25, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine
April 22, 2025
·
8 min read
Press Releases
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 million Management to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024
February 6, 2025
·
24 min read
Press Releases
Inventiva announces completion of enrollment in the Phase 3 NATiV3 clinical trial of lanifibranor in patients with MASH and advanced fibrosis
April 2, 2025
·
12 min read
Mergers & acquisitions
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences market, recently revitalized by more industry-friendly policy changes from the government.
February 10, 2025
·
1 min read
·
Tristan Manalac
Press Releases
Title restor3d receives FDA Clearance for iTotal IdentityTM CR 3DP Porous Fully Personalized Total Knee Replacement System
April 1, 2025
·
4 min read
Press Releases
Patent Granted to BC3 Technologies for SEAL Hemostatic Wound Spray
April 16, 2025
·
4 min read
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
Ferring Announces Initial Data from Phase 3 Trial in Japanese Patients Demonstrating 75% Complete Response Rate at 3 Months with (nadofaragene firadenovec) in BCG-unresponsive NMIBC Patients1
April 21, 2025
·
9 min read
Press Releases
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
March 20, 2025
·
16 min read
1 of 29,240
Next
